Monitoring in all steroid-sparing agents
| When | What |
| Pretreatment | FBC, U&E, eGFR, LFT, albumin, beta-HCG |
| Monitoring | Every 2 weeks until dose stable for at least 6 weeks: FBC, U&E, eGFR, LFT, albumin |
| Monthly for first 3 months on stable dose: FBC, U&E, LFT, albumin | |
| Then every 3 months: FBC, U&E, LFT, albumin | |
| Following dose change | Every 2 weeks until dose stable for at least 6 weeks: FBC, U&E, eGFR, LFT, albumin |
beta-HCG, beta human chorionic gonadotrophin; eGFR, estimated glomerular filtration rate; FBC, full blood count; LFT, liver function tests; U&E, urea and electrolytes.